Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Stumvoll, M
It is intended to provide information for people who are concerned about how GLP-1 medications may be interacting with their eating, or who have a history of disordered eating and want to understand the potential risks
2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events A 2024 Meta-analysis of 13 multiple cardiovascular outcome trials has documented that GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
These effects are often more pronounced during the initial stages of treatment as the body adjusts to the medication
It may also assist in improving sleep quality for those with sleep apnea
Semaglutide & eye health: Can it cause vision problems
US$ 22.59
US$ 24.75
US$ 21.44
